A Company You Can Count On - Company Overview

With LifebankUSA™ you can have the utmost confidence in your choice. LifebankUSA and its parent organization, Celgene® Corporation, are both established companies with a proven history and a viable future. And that’s important when you are making the important decision to bank stem cells from your baby’s placenta and umbilical cord.

LifebankUSA was founded in 1998 by a team of stem cell research scientists and practicing physicians and has been successfully banking umbilical cord blood and stem cells since that time. LifebankUSA has an experienced, dedicated staff with scientists committed to furthering stem cell therapies and fostering advancements in placental and umbilical cord blood banking. LifebankUSA introduced placental stem cell banking to the world in early 2006. Plus, we have a proven track record of banking and releasing stem cells for transplant.

As an umbilical cord blood bank and the world’s first Placenta•Cord™ bank, LifebankUSA has always had a strong commitment to furthering the possibilities of stem cell therapy and has been actively involved in research and discovery since the beginning. We understand that the value of banking stem cells from the umbilical cord blood and placenta depends on the medical advances that are made in stem cell therapeutics—and we have made a commitment to take an active role in the pursuit of those placental and cord blood advances. We also collaborate with some of the nation’s premier medical institutions to help advance therapies using placental and cord blood stem cells. This heavy emphasis on research and discovery, and the focus on the future of placental stem cells, sets LifebankUSA apart from other umbilical cord blood banks.

LifebankUSA is owned by Celgene Corporation, a publicly traded company with disclosed market capitalization of more than $10 billion. Since its inception in 1986, Celgene has a proven commitment to the discovery and development of innovative therapies for the treatment of cancer and inflammatory diseases. Headquartered in Summit, New Jersey, Celgene is a successful and stable company. And because it is publicly traded on the NASDAQ stock exchange (CELG), you get the added confidence that goes along with the high business standards all publicly held companies must satisfy. 

The chance that a child will use his/her own stored cord blood stem cells during their lifetime is estimated at 1 in 400 (J.J. Nietfeld and F. Verter). These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the cord blood stem cells collected, the HLA compatibility between recipient and donor, and the client’s overall health.